Your browser doesn't support javascript.
loading
Effects of Simvastatin Alone or Combined With Ramipril on Nitric Oxide Bioactivity and Inflammation Markers in Hypercholesterolemic Patients
Korean Circulation Journal ; : 1053-1059, 2003.
Artículo en Coreano | WPRIM | ID: wpr-54865
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Because the mechanisms of the biological effects of statin and antiotensin converting enzyme inhibitor therapies differ, the vascular responses to these therapies were studied in hypercholesterolemic patients. MATERIALS AND

METHODS:

Simvastatin, 20 mg, placebo or ramipril, 10 mg, were administered daily for 2 months, with a 2 month washout, to 32 hypercholesterolemic patients. This was a randomized, double-blind, placebo-controlled, crossover in design study.

RESULTS:

Simvastatin alone, or in combination with ramipril, significantly changed the lipoproteins, and improved the percentage of the flow-mediated dilator response to hyperemia by 46+/-48% and by 59+/-66%, respectively, relative to the baseline measurements (both p<0.001). The plasma malondialdehyde levels were reduced, relative to baseline measurements, by 6+/-57% (p=0.045) and 13+/-47% (p=0.045 and p<0.001, respectively) and plasma levels of monocyte chemoattractant protein-1 by 3+/-27% and by 9+/-16%, respectively (p=0.113 and p=0.001, respectively). The C-reactive protein were also reduced, relative to baseline measurements, by 17+/-75% and by 17+/-37%, respectively (p=0.003 and p=0.001, respectively). However, simvastatin combined with ramipril changed, to a greater extent, but was statistically insignificant, the percentage of the flow-mediated dilator response to hyperemia, and the plasma monocyte chemoattractant protein-1 levels, than simvastatin alone.

CONCLUSION:

Compared with simvastatin alone, the addition of ramipril improved the endothelial function to greater extent, but was statistically insignificant, in hypercholes-terolemic patients.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Plasma / Proteína C-Reactiva / Ramipril / Quimiocina CCL2 / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Simvastatina / Hiperemia / Inflamación / Lipoproteínas / Malondialdehído Tipo de estudio: Ensayo Clínico Controlado Límite: Humanos Idioma: Coreano Revista: Korean Circulation Journal Año: 2003 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Plasma / Proteína C-Reactiva / Ramipril / Quimiocina CCL2 / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Simvastatina / Hiperemia / Inflamación / Lipoproteínas / Malondialdehído Tipo de estudio: Ensayo Clínico Controlado Límite: Humanos Idioma: Coreano Revista: Korean Circulation Journal Año: 2003 Tipo del documento: Artículo